Dr. Savidge's research interests include studying microbial-neuroimmune interactions in the gastrointestinal tract and nervous systems. This work has established new disease susceptibility biomarkers to Clostridium difficile infection and Fecal Microbiota Transplantation failure, as well as identifying new precision-based microbial therapy for recurrent C. difficile infection based on population-scale metagenomics and functional microbiome analysis.
Recurrent C. Difficile Infection In Adults And Children: Precision-Based Diagnosis And Aicrobiota Therapy
This talk will cover Dr. Savidge's research on predicting patient susceptibility to C. difficile infection and clinical fecal microbiota treatment failures. His lab is also utilizing population-scale omics data to rationally design new microbial therapy for recurrent C. difficile infection.
Understanding mechanism of action and translating microbiome science into commercially viable therapeutics remains the biggest challenge in this emerging field. With that said, pharma and biotech across many different therapeutic indications and modalities are united in this global effort to bring novel microbiome-based therapies and diagnostics into the clinical domain. This session will include some of the most impactful and promising areas of the microbiome field: